DEAR DR. ROACH: My father is 91 years old, and I am concerned that his elevated blood pressure isn't being properly addressed. Recently, it seems to run in the mid-170s to mid-80s (176/86). He has a number of health issues, such as a kidney stent every three months, diabetic neuropathy and a transient ischemic attack. He takes metoprolol (25 mg in the morning and evening). I sent a note to his doctor suggesting his blood pressure meds need to be reevaluated, and the doctor's response was to check his blood pressure several times daily for a month then let him know the average. He said the goal was an average blood pressure below 160/90 more than half the time.
I think a goal of 160 is too high and that four weeks is too long to wait before deciding if his meds need to be adjusted. I would like your opinion. -- L.F.
ANSWER: Your father's doctor may not want to use too many blood pressure medicines and cause symptoms that could affect your father's quality of life at age 91. On the other hand, a goal of 160/90 is not optimal, especially for someone who has already had a TIA (transient ischemic attack, which is often a predictor of a stroke). I think it's likely that your father could take medicines that control the blood pressure better but don't cause much if anything in terms of side effects.
A person with diabetes and high blood pressure, especially one who already has a complication like neuropathy, is at high risk for developing kidney disease from diabetes. ACE inhibitor drugs help reduce that risk as well as reduce the risk of heart attack, so I am very surprised he is not taking one. A beta blocker alone, like metoprolol, is not likely to be effective.
There remains some controversy about the ideal blood pressure goal for a person in your father's position. One recent study would suggest a goal of 120 is better than the older goal of less than 140. However, the blood pressure goal needs to be individualized. Side effects from blood pressure medications need to be carefully managed and may sometimes keep a person from reaching their goal. Still, blood pressure above 160 is not adequate control.
As far as timing, it's best to get as much data as possible before making a change in blood pressure medication. Four weeks is usually reasonable, but with your father's too-high blood pressure, two weeks should be enough time to confirm high blood pressures at home.
DEAR DR. ROACH: Do you think we will get sick from 5G towers? I have read that we will, but also that we won't. -- T.K.
ANSWER: Many studies have been done to look at health risks of radiation from cellphones and towers. After much research, there have been no health risks confirmed.
The main difference between 5G and previous cellphone radiation is the higher frequency of the electromagnetic radiation. Higher frequency may sound scary, but there is less penetration into the body than a lower frequency. This type of energy is non-ionizing and simply doesn't have the energy to damage DNA.
Readers may email questions to ToYourGoodHealth@med.cornell.edu. (c) 2020 North America Syndicate Inc.
Follow this link:
Roach: Optimal blood pressure goal needs to be individualized - LubbockOnline.com
- Peripheral neuropathy: Causes, symptoms, treatment, and prevention - September 21st, 2024
- Sponsored: Say goodbye to neuropathy with help from NexGenEsis Healthcare - KHOU.com - September 21st, 2024
- Danish Study Reveals Connection Between Diabetic Neuropathy, Retinopathy, and Severe Periodontitis - Medical Dialogues - September 21st, 2024
- What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes - July 30th, 2024
- Neuropathy | Duke Health - October 16th, 2023
- Peripheral Neuropathy | University Hospitals - May 9th, 2023
- Cranial Neuropathies | University Hospitals - May 9th, 2023
- Treatment for Peripheral Neuropathy & Other Nerve Damage | University ... - May 9th, 2023
- Neuromuscular Disease | Facts About Neuromuscular Disorders, Symptoms ... - May 9th, 2023
- Patrick McIntyre MD, JD Doctor Profile & Reviews | University Hospitals - May 9th, 2023
- Peripheral Neuropathy: What It Is, Symptoms & Treatment - Cleveland Clinic - May 1st, 2023
- Peripheral Neuropathy | National Institute of Neurological Disorders ... - May 1st, 2023
- Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study... - May 1st, 2023
- Successfully Treating Diabetic Neuropathy at Vero Neuropathy | Paid Content - Local 5 - weareiowa.com - May 1st, 2023
- Peripheral Neuropathy Treatment at Advanced Nerve and Health Center - WFAA.com - May 1st, 2023
- Different Types of Peripheral Neuropathy | Paid Content - Local 5 - weareiowa.com - February 24th, 2023
- Peripheral neuropathy: Symptoms, causes, and treatment - Medical News Today - February 24th, 2023
- Natural Treatments for Peripheral Neuropathy - Healthline - December 28th, 2022
- Diabetic neuropathy types: Symptoms tell the story - Mayo Clinic - December 28th, 2022
- Supplements for Neuropathy: Vitamins and More - Healthline - December 28th, 2022
- The Effectiveness of Topical Cannabidiol Oil in Symptomatic ... - PubMed - December 28th, 2022
- Autonomic neuropathy - Diagnosis and treatment - Mayo Clinic - December 28th, 2022
- Peripheral neuropathy - Causes - NHS - December 28th, 2022
- Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and ... - PubMed - December 28th, 2022
- What Is Auditory Neuropathy? Causes & Treatment | NIDCD - December 20th, 2022
- Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content - Local 5 - weareiowa.com - December 20th, 2022
- Neuropathy No More Reviews (Blue Heron Health News) Does It Work? - Outlook India - December 20th, 2022
- Neuropathy Pain Treatment Market Size to Grow by USD 3.81 Bn, Growing Focus on Emerging Economies to be a Key Trend - Technavio - Yahoo Finance - October 7th, 2022
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 7th, 2022
- Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics... - October 7th, 2022
- Side effects that may arise during breast cancer treatment The Hamburg Reporter - Hamburg Reporter - October 7th, 2022
- Neuropathy & the Truth About Alternative Care - North Forty News - June 16th, 2022
- Chemotherapy-Induced Peripheral Neuropathy: The Invisible Side Effect - Curetoday.com - June 16th, 2022
- Thermal gradient ring reveals thermosensory changes in diabetic peripheral neuropathy in mice | Scientific Reports - Nature.com - June 16th, 2022
- GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022 - Business Wire - June 16th, 2022
- Warning Signs of Diabetes, Says Physician Eat This Not That - Eat This, Not That - June 16th, 2022
- Foot Disease: The Most Feared Of All The Consequences Of Diabetes - Pressat - June 16th, 2022
- How Mindfulness Meditation May Help Ease Stress and Anxiety in Cancer Survivors, and Where to Start - Curetoday.com - June 16th, 2022
- TYPES OF CANNABIS STRAINS AND THE TYPE OF PAIN THEY TREAT - GISuser.com - June 16th, 2022
- 5 Types of Neuropathy and What to Do About Them | Fort ... - April 26th, 2022
- Unilateral Compressive Optic Neuropathy As the Presenting Manifestation of Clival Chordoma: A Case Report - Cureus - April 26th, 2022
- A Case of Secondary Trigeminal Neuropathy Due to Local Malignant Invasion of the Maxillary and Mandibular Nerves at the Skull Base: A Case Report With... - April 26th, 2022
- Global Leber's Hereditary Optic Neuropathy Drug Market 2022 to 2031 Analysis themobility.club - themobility.club - April 26th, 2022
- Risks of vitamin B12 deficiency and the symptoms to look out for - My London - April 26th, 2022
- NeuraLace announces two new patents for Axon neuropathic pain therapies - NeuroNews International - April 26th, 2022
- Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York... - April 26th, 2022
- Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com - November 21st, 2021
- AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire - November 21st, 2021
- Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes - November 21st, 2021
- Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express - November 21st, 2021
- Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News - November 21st, 2021
- Broadway Vascular Announces Top-Line Results of 12-Month Retrospective Analysis Evaluating Revascularization of the Lateral Plantar Artery in Diabetic... - October 26th, 2021
- Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency - Yahoo Finance - October 26th, 2021
- Heres Why Alger Sold its Nevro Corp. (NVRO) Position - Yahoo Finance - October 26th, 2021
- Zika virus in UP: Symptoms, treatment and other things to know - Hindustan Times - October 26th, 2021
- Ask the GP: Why do my feet feel like they're on fire? - The Irish News - October 26th, 2021
- For veterans: VA prepares to tackle backlogged disability claims - The Herald-Times - October 26th, 2021
- Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help... - August 17th, 2021
- Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace - August 17th, 2021
- CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News - August 17th, 2021
- Spotlight on ultrasonography in the diagnosis of PND | IJGM - Dove Medical Press - August 17th, 2021
- Eye scan could determine whether COVID patients will be long haulers - WGNO New Orleans - August 17th, 2021
- Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly - The Manomet Current - August 17th, 2021
- The Feather and the Knife: Navigating Life With Chronic Pain - POZ - August 17th, 2021
- Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing - Yahoo Finance - August 17th, 2021
- Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Yahoo Finance - August 17th, 2021
- Ugly Side Effects of Too Many Vitamins - Eat This Not That - Eat This, Not That - August 17th, 2021
- Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain - Digital... - May 14th, 2021
- Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy - BioSpace - May 14th, 2021
- Global Chronic Pain associated with Painful Diabetic Neuropathy Market to 2025 - Insight, Competitive Landscape and Forecasts - ResearchAndMarkets.com... - May 14th, 2021
- Leber's Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Will Accelerate at a CAGR Through 2021-2027 | Rising Technological Innovations... - May 14th, 2021
- Chemotherapy induced peripheral neuropathy Pipeline Insight to See Strong Expansion Through 2027 Covid-19 Analysis The Courier - The Courier - May 14th, 2021
- Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight -... - May 14th, 2021
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19 - Business Wire - May 14th, 2021
- Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2... - May 14th, 2021
- Phenotypic Stratification of Patients With Painful Neuropathy May Predict Response to Therapy - Clinical Pain Advisor - May 2nd, 2021
- Peripheral Neuropathy Treatment Market: Development, Growth, Trends, Demand, Analysis and Forecast 2026 KSU | The Sentinel Newspaper - KSU | The... - May 2nd, 2021
- Diabetic Neuropathy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 The Courier - The Courier - May 2nd, 2021
- Leber's Hereditary Optic Neuropathy Drug Market Size and Forecast 2027 | Top Key Players Alkeus Pharmaceuticals, Ixchel Pharma, LLC, Biovista Inc.,... - May 2nd, 2021
- There are treatment options for neuropathy | News, Sports, Jobs - SalemNews.net - March 3rd, 2021